Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Overexpressed Long Non-Coding RNA SATB2-AS1 Inhibits microRNA-155-3p to Suppress Breast Cancer Cell Growth by Promoting BRMS1L
36 Pages Posted: 10 Aug 2020
More...Abstract
Objective: Recently, Fas ligand (Fasl) and exosomes have been reported to regulate the progression of breast cancer (BC), we aim to explore the function mechanisms of Fasl and NK-92 cell-derived exosomes (NK-92 Exo) in BC.
Methods: Fasl expression in BC tissues and cells was assessed, and BC cell lines which have the most (MCF-7 cells) and least (Hs578T cells) difference in Fasl expression from MCF10A cells were screened. The exosomes were extracted from NK-92 cells (NK-92 Exo), and then the MCF-7 and Hs578T cells were co-cultured with NK-92 cells or NK-92 Exo, and respectively treated with overexpressed or silenced Fasl, then the proliferation, invasion, migration and apoptosis of BC cells were determined. The tumor growth was observed through subcutaneous tumorigenesis in nude mice.
Results: Fasl was reduced in BC tissues and cell lines. The overexpressed Fasl, NK-92 cells and NK-92 Exo were able to inhibit proliferation, invasion and migration, while promote apoptosis of BC cells in vitro, and could also decelerate BC tumor growth in vivo.
Conclusion: NK-92 Exo overexpressing Fasl could promote apoptosis of BC cells through apoptotic signaling pathways, which may provide a theoretical basis for application of Fasl in BC.
Funding Statement: The study was supported by National Natural Science Foundation of China (81673006) and Petrel Foundation of Harbin Medical University Cancer Hospital (JJZD2020-10).
Declaration of Interests: The authors declare that they have no conflicts of interest.
Ethics Approval Statement: All patients provided written informed consents before this study. The protocol of this study was confirmed by the Ethic Committee of Harbin Medical University Cancer Hospital. The protocol of animal experiments was approved by the Institutional Animal Care and Use Committee of Harbin Medical University Cancer Hospital.
Keywords: Breast cancer; Exosome; Fas ligand; NK-92 cell; apoptosis; Proliferation
Suggested Citation: Suggested Citation